Scarica l'app Stockscreener
2.60
5.45%
-0.15
Dopo l'orario di chiusura:
2.56
-0.04
-1.54%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché ADIL Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.75
Aprire:
$2.79
Volume 24 ore:
153.58K
Relative Volume:
0.34
Capitalizzazione di mercato:
$5.69M
Reddito:
-
Utile/perdita netta:
$-7.77M
Rapporto P/E:
-0.2625
EPS:
-9.9046
Flusso di cassa netto:
$-6.52M
1 W Prestazione:
-12.75%
1M Prestazione:
+61.49%
6M Prestazione:
-60.28%
1 anno Prestazione:
-56.49%
Intervallo 1D:
$2.56
$2.8993
Intervallo di 1 settimana:
$2.402
$3.14
Portata 52W:
$1.31
$18.90
Adial Pharmaceuticals Inc Stock (ADIL) Company Profile
Nome
Adial Pharmaceuticals Inc
Settore
Industria
Telefono
434-422-9800
Indirizzo
1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
Compare ADIL vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ADIL
Adial Pharmaceuticals Inc
|
2.60 | 5.69M | 0 | -7.77M | -6.52M | -9.9046 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Adial Pharmaceuticals Inc Stock (ADIL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-14 | Iniziato | Rodman & Renshaw | Buy |
| 2018-10-30 | Iniziato | Maxim Group | Buy |
| 2018-10-11 | Iniziato | Dawson James | Buy |
Adial Pharmaceuticals Inc Borsa (ADIL) Ultime notizie
Net current asset value per share of Adial Pharmaceuticals, Inc – NASDAQ:ADIL - TradingView
ADIL stock eyes best day in over 5 years — major pipeline overhaul and $64M raise fuel rally - MSN
Adial Pharmaceuticals Inc (ADIL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Adial Pharmaceuticals Inc (ADIL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Adial Pharmaceuticals Inc (ADIL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Adial Pharmaceuticals Inc (ADIL) Institutional Confidence - TradingKey
Adial Pharmaceuticals Inc (ADIL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Adial Pharmaceuticals Inc (ADIL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Adial Pharmaceuticals Inc (ADIL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Adial Pharmaceuticals Inc (ADIL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Adial closes $32 million financing, grants stock to new executives By Investing.com - Investing.com South Africa
Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing - marketscreener.com
Biotech funds back Adial with $32M for colon-targeted program - Stock Titan
Adial Pharmaceuticals (ADIL) CDO adds RSUs, options and preferred shares after Azora merger - Stock Titan
ADIAL (ADIL) director and CDO Matt Davidson listed in Form 3 filing - Stock Titan
ADIAL (ADIL) director Wendy Young files initial insider Form 3 statement - Stock Titan
Adial Pharmaceuticals Inc (ADIL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ADIL Initiates Coverage by LUCID CAPITAL MARKETS -- Rating Set to Buy - GuruFocus
Lucid Capital Markets initiates Adial Pharmaceuticals stock with buy rating on colitis drug potential - Investing.com UK
Adial Pharmaceuticals (ADIL) Holds Steady at $2.98 as Consolidation NarrowsIchimoku Kumo Twist - newsline.com
ADIL Stock Eyes Best Day In Over 5 Years — Major Pipeline Overhaul And $64M Raise Fuel Rally - Stocktwits
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Adial broadens pipeline with Azora acquisition and up to $64 million financing - The Pharma Letter
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Top Midday Gainers - Moomoo
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Adial Pharmaceuticals (ADIL) Acquires Azora Therapeutics and Sec - GuruFocus
Top movers analysis one hour before the close of the markets on 2026-06-11: top gainers and losers in today's session. - ChartMill
Adial Pharmaceuticals (ADIL) Acquires Azora Therapeutics to Enha - GuruFocus
Adial Pharmaceuticals Announces Acquisition Of Azora Therapeutics And Up To $64 Million Financing - TradingView
Adial Pharmaceuticals, Inc. (ADIL) Stock: Strategic Acquisition Positions Company for Clinical Growth - parameter.io
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Adial Pharmaceuticals Acquires Azora and Raises $26.8M PIPE, With More on Milestones - TradingView
Adial Pharmaceuticals acquires Azora Therapeutics for $32M By Investing.com - Investing.com South Africa
Adial (NASDAQ: ADIL) acquires Azora and lines up up to $64M for UC drug - Stock Titan
Adial Pharmaceuticals acquires Azora Therapeutics for $32M - Investing.com
ADIAL PHARMACEUTICALSENTERS AGREEMENT FOR UP TO $64 MLN PRIVATE PLACEMENT - Moomoo
Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing - GlobeNewswire
Colon‑targeted ulcerative colitis drug draws up to $64M funding - Stock Titan
Adial Pharmaceuticals acquires Azora Therapeutics and raises up to $64M to advance ulcerative colitis treatment. - Pluang
Adial's Acquisition of Azora Boosts Stock Price by 110% - Intellectia AI
Adial Pharmaceuticals(ADIL) Stock Options Chain | Quotes & News - Moomoo
Adial Pharmaceuticals, Inc. Financial Disclosures & SEC Filings - TradingView
Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight - GlobeNewswire Inc.
ADIL Q1 2026 Earnings: Narrowed Loss Beats Expectations as Biotech Advances PipelineRevenue Inflection Point - newsline.com
Adial Pharmaceuticals Stock Faces Crucial AD04 Funding Test After Holiday Break - Bez Kabli
Adial Pharmaceuticals (ADIL) Surges 7.69%: Breaking Above Key SupportIchimoku Kumo Break - newsline.com
Adial Pharmaceuticals (ADIL) Drops 9.57% as Selling Pressure Mounts Near Key SupportDescending Triangle - The Legal Advocate
Adial Pharmaceuticals (ADIL) Q1 2026 Earnings: Narrower-Than-Expected Loss as Operational Progress ContinuesROIC Trend Report - newsline.com
ADIL Q1 2026 Earnings: Narrowed Loss Beats Estimates, but Market Remains CautiousEPS Revision Trend - newsline.com
ADIL Q1 2026 Earnings: Narrowing Loss Beats Estimates, But Stock Declines Amid No RevenuePost-Earnings Reaction - Newser
Adial Pharmaceuticals Inc Azioni (ADIL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):